FDA will gain more flexibility in how it can push applications through its review system in PDUFA VI, including gaining the ability to avoid some required interactions with the sponsor.
It is a subtle but important refinement of what has become known as the "Program" for NDA and BLA reviews...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?